OPHLY:OTCMKTS
Ono Pharmaceutical ADR Representing 1/3rd Ord Shs
4,76 USD
arrow_upward
+0,85%(+0,040) 1 zi
13 oct., 16:00:00 GMT-4 · USD
search
Toate simbolurile
| Simbol | Preț | Modificare | Modificare % |
|---|
insights_autoSe generează principalele statistici pentru OPHLY...
Deschide
4,78 USD
Mare
4,78 USD
Mic
4,76 USD
Capitalizarea bursieră
1,13 tril.
Volum mediu
60,13 K
Volum
82,82 K
Prețul ridicat pe 52 de săptămâni
5,75 USD
Prețul redus pe 52 de săptămâni
3,81 USD
Beta
0,21
Acțiuni aflate în circulație
1,50 mld.
Nr. de angajați
4 K
Deschide
4,78 USD
Mare
4,78 USD
Mic
4,76 USD
Capitalizarea bursieră
1,13 tril.
Volum mediu
60,13 K
Volum
82,82 K
Prețul ridicat pe 52 de săptămâni
5,75 USD
Prețul redus pe 52 de săptămâni
3,81 USD
Beta
0,21
Acțiuni aflate în circulație
1,50 mld.
Nr. de angajați
4 K
Subiecte de știri
Din surse web și de la parteneri de știri
Vietnam.vn
·
acum 23 de ore
Indicele compozit Nasdaq a scăzut înainte de sezonul de raportare a rezultatelor financiare.
Vietnam.vn
·
acum 23 de ore
Acțiuni americane: Indicele compozit Nasdaq scade înainte de sezonul de raportare a rezultatelor financiare.
The Globe and Mail
·
acum 59 de minute
Kaplan Fox Encourages Fluence Energy, Inc. (NASDAQ: FLNC) Investors to Contact the Firm Before the Lead Plaintiff Deadline on November 27, 2026
Profil
Ono Pharmaceutical Co., Ltd. is one of the largest pharmaceutical companies in Japan. It is headquartered in Chuo-ku, Osaka, Japan, with its major plants in Higashinari-ku, Osaka, and Fujinomiya, Shizuoka., and its central research institute at Minase, Shimamoto-cho, Mishima District, Osaka.
Ono Pharmaceutical's roots go back to 1717 when Ichibei Ono started his dealer business of pharmaceuticals in Osaka. His business expanded and changed its name a few times, and became Ono Pharmaceutical Industrial Co., Ltd. in 1948.
Ono has been listed in Tokyo Stock Exchange since 1963. Its consolidated earnings in the half year ending in March 2018 were 16 billion Japanese yen.
Nivolumab, the cancer drug based on the research of Prof. Dr. Tasuku Honjo of Kyoto University, who received the Nobel Prize later in 2018, is marketed by both Ono Pharmaceutical and Bristol-Myers Squibb.
In 2024, Harvard University and Ono Pharmaceutical entered into a joint research and drug development agreement. Under it, promising projects to test therapeutic targets will be selected over 5 years under the guidance of Harvard's Office of Technology Development, and ONO will fund the work. Wikipedia
Despre Ono Pharmaceutical ADR Representing 1/3rd Ord Shs
Director executivGyo Sagara | Gyo Sagara
Angajați4,21 K
Înființată la1717
SediuOsaka, Prefectura Osaka, Japonia
Domeniu-
Siteono-pharma.com